SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission
Peter S. Hamblin(The University of Melbourne), Leon A. Bach(Monash University), Elif I. Ekinci(The University of Melbourne), Spiros Fourlanos(The Royal Melbourne Hospital), Mervyn Kyi(The Royal Melbourne Hospital), Rinky Giri, Sonali Shah(Monash Health), Debra Renouf(Peninsula Health), Richard J. MacIsaac, Brendan J. Nolan(Northern Health), Sylvia Xu(Peninsula Health), Elizabeth George(The Ohio State University), David N. O’Neal(Baker Heart and Diabetes Institute), Dilan Seneviratne Epa(St Vincent's Hospital Melbourne), Jennifer L. Wong(Monash Health), M. J. Hare(Royal Darwin Hospital), Alicia Jones(Monash Health), Nicole Lafontaine(Eastern Health), Rosemary Wong(Eastern Health), Genevieve Calder(St Vincent's Hospital Melbourne), Suresh Varadarajan(Northern Health), Mark A. Kotowicz(Barwon Health)
Cited by 122
Related Papers
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men
|American Journal of Clinical Nutrition|2000|586
Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway
|Diabetes|2007|346
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
|Clinical Infectious Diseases|2018|256
Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report
|Diabetes Care|2016|215